Long-term Maintenance of Remission with No Dose Escalation Aft er Re-induction with Certolizumab Pegol in Patients with Crohn's Disease Exacerbation: 3-year Results from the PRECiSE 4 Study

被引：0
|
作者：
Sandborn, William [1 ]
Schreiber, Stefan [2 ]
Hanauer, Stephen [3 ]
Colombel, Jean-Frederick [4 ]
Bloomfield, Ralph [5 ]
Lichtenstein, Gary [6 ]
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Univ Kiel, Kiel, Germany
[3] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[4] Hop Claude Huriez, Lille, France
[5] UCB Pharma, Slough, Berks, England
[6] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2009年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1207
引用
收藏
页码：S448 / S448
页数：1
相关论文
共 50 条
  • [1] Long-term maintenance of remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohn's disease exacerbation: 3-year results from the PRECiSE 4 study
    Sandborn, W.
    Schreiber, S.
    Hanauer, S.
    Colombel, J.
    Bloomfield, R.
    Lichtenstein, G.
    [J]. INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) : S14 - S14
  • [2] Sustained Remission with No Dose Escalation after Re-induction with Certolizumab Pegol in Patients with Crohn's Disease Exacerbation: 1-Year Results from PRECiSE 4
    Sandborn, William
    Rubin, David
    Sen, David
    Feagan, Brian
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S439 - S439
  • [3] Long-term Maintenance of Remission with No Dose Escalation After Re-induction with Certolizumab Pegol in Patients with Crohn's Disease Exacerbation Who Were Naive to Anti-TNF Treatment: 4-Year Results from the PRECiSE 4 Study
    Sandborn, William
    Schreiber, Stefan
    Hanauer, Stephen
    Colombel, Jean-Frederic
    Bloomfield, Ralph
    Lichtenstein, Gary
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S418 - S418
  • [4] Remission Rates in Crohn's Disease Patients Treated With a Re-Induction Regimen of Certolizumab Pegol After Experiencing Disease Exacerbation: 7 Year Results From the Precise 4 Study
    Lee, Scott D.
    Schreiber, Stefan
    Schwartz, David A.
    Burakoff, Robert
    Binion, David G.
    Kayhan, Cem
    Kosutic, Gordana
    Ambarkhane, Sumeet
    Sen, David
    Hasan, Iram
    Spearman, Marshall
    Sandborn, William
    [J]. GASTROENTEROLOGY, 2015, 148 (04) : S261 - S261
  • [5] Sustained Remission With No Dose Escalation After Re-Induction With Certolizumab Pegol in Patients With Crohn's Disease Exacerbation Who Were NaiVE to Anti-TNF Treatment: 5-Year Results From Precise 4
    Sandborn, William J.
    Schreiber, Stefan
    Colombel, Jean-Frederic
    Sen, David L.
    Lichtenstein, Gary R.
    [J]. GASTROENTEROLOGY, 2011, 140 (05) : S65 - S66
  • [6] Sustained remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohn's disease exacerbation who were naive to anti-TNF treatment: 5-year results from PRECiSE 4
    Sandborn, William J.
    Schreiber, Stefan
    Colombel, Jean-Frederic
    Sen, David
    Lichtenstein, Gary R.
    [J]. INFLAMMATORY BOWEL DISEASES, 2011, 17 : S24 - S24
  • [7] Sustained remission with no dose escalation after re-induction with certolizumab pegol in patients with Crohn's disease exacerbation who were naive to anti-TNF treatment: 4-year results from PRECiSE 4.
    Sandborn, W.
    Schreiber, S.
    Hanauer, S.
    Colombel, J.
    Bloomfield, R.
    Lichtenstein, G.
    [J]. INFLAMMATORY BOWEL DISEASES, 2011, 17 : S60 - S60
  • [8] Incidence and Predictors of Clinical Response, Re-induction Dose, and Maintenance Dose Escalation with Certolizumab Pegol in Crohn's Disease
    Stein, Adam C.
    Rubin, David T.
    Hanauer, Stephen B.
    Cohen, Russell D.
    [J]. INFLAMMATORY BOWEL DISEASES, 2014, 20 (10) : 1722 - 1728
  • [9] Long-Term Outcomes of Certolizumab Pegol for Crohn's Disease: 7 Year Results From the PRECiSE 3 Study
    Sandborn, William
    Lee, Scott D.
    Randall, Charles W.
    Gutierrez, Alexandra
    Schwartz, David A.
    Ambarkhane, Sumeet
    Kayhan, Cem
    Pierre-Louis, Bosny
    Kosutic, Gordana
    Schreiber, Stefan
    Lichtenstein, Gary R.
    [J]. GASTROENTEROLOGY, 2014, 146 (05) : S588 - S589
  • [10] Long-term remission with certolizumab pegol in Crohn's disease over 3.5 years: results from the PRECiSE 3 study
    Lichtenstein, G.
    Thomsen, O.
    Schreiber, S.
    Lawrance, I
    Hanauer, S.
    Bloomfield, R.
    Sandborn, W.
    [J]. INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) : S12 - S13
12345